Clinical Trials Sponsored by Taiwanese Gynecologic Oncology Group

Total 289 results

Chang Gung Memorial Hospital
Asian Gynecologic Oncology Group; Taiwanese Gynecologic Oncology Group

Recruiting

Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy

Cervical Cancer

Taiwan
Chang Gung Memorial Hospital
Hoffmann-La Roche; Asian Gynecologic Oncology Group; Taiwanese Gynecolgic Oncology...

Completed

Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer

Epithelial Ovarian Cancer

Taiwan
Japanese Gynecologic Oncology Group
Korean Gynecologic Oncology Group

Recruiting

Phase III Trial of Stage I Ovarian Cancer After Surgery

Epithelial Ovarian Cancer

Japan, Korea, Republic of
Shanghai Gynecologic Oncology Group

Recruiting

Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

Korea, Republic of, China
Korean Gynecologic Oncology Group

Unknown

Management of Endometrial Hyperplasia With a LNG-IUS: Multicenter Study: KGOG2006 (KGOG2006)

Endometrial Hyperplasia

Korea, Republic of
Korean Gynecologic Oncology Group

Completed

A Safety and Efficacy of CCRT With Paclitaxel/Carboplatin as Adjuvant Therapy to Post-operative Cervical Cancer Patients

Cervical Cancer

Korea, Republic of
Sanofi
Gynecologic Oncology Group

Completed

Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma

Uterine Carcinosarcoma

United States
Korean Gynecologic Oncology Group

Unknown

Treatment With Medroxyprogesterone Acetate Plus LNG-IUS in Young Women With Early Stage Endometrial Cancer

Endometrial Cancer

Korea, Republic of
Korean Gynecologic Oncology Group

Unknown

Adjuvant Chemotherapy in Patients With Lymph Node Metastasis After Radical Surgery in Cervical Cancer

Cervical Cancer

Korea, Republic of
Japanese Gynecologic Oncology Group

Completed

Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

Japan
Celgene
Gynecologic Oncology Group

Completed

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States
Korean Gynecologic Oncology Group

Unknown

Comparison of Dilatation & Curettage and Endometrial Aspiration Biopsy Accuracy in Patients Treated With Progestin for Endometrial Hyperplasia: A Korean Gynecologic Oncology Group Study

Endometrial Hyperplasia

Korea, Republic of
Korean Gynecologic Oncology Group

Unknown

A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

Korea, Republic of
Korean Gynecologic Oncology Group

Unknown

A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients

Endometrial Cancer

Korea, Republic of
Gynecologic Oncology Trial & Investigation Consortium
Japanese Gynecologic Oncology Group

Completed

Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial (iPocc)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

Japan, United States, Hong Kong, Korea, Republic of, New Zealand, Singapore
Gynecologic Oncology Group

Completed

Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Tesaro, Inc.
Gynecologic Oncology Group

Terminated

Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer (MOONSTONE)

Ovarian Neoplasms

United States
ImmunoGen, Inc.
Gynecologic Oncology Group

Completed

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (FORWARD I)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

United States, France, Canada, Spain, Switzerland, Belgium, Italy, United Kingdom, Ireland, Russian Federation, Bosnia and Herzegovina, Czechia, Serbia
Corcept Therapeutics
Gynecologic Oncology Group

Active, not recruiting

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Fallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian Neoplasm

United States, Argentina, Australia, Belgium, Brazil, Canada, France, Hungary, Israel, Italy, Korea, Republic of, Poland, Spain, United Kingdom
Advaxis, Inc.
Gynecologic Oncology Group

Terminated

Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer (AIM2CERV)

High Risk Cervical Cancer | Advanced Cervical Cancer

United States, Argentina, Brazil, Canada, Chile, Korea, Republic of, Malaysia, Mexico, Poland, Russian Federation, Serbia, Spain, Taiwan, Ukraine
Chinese Gynecological Oncology Group

Unknown

Comparison of Class II and Class III Hysterectomy in Early Stage Cervical Cancer Cervical Cancer

Cervical Cancer
Gynecologic Oncology Group
Novartis

Active, not recruiting

Ribociclib and Letrozole Treatment in Ovarian Cancer

Low Grade Serous Carcinoma

United States
Gynecologic Oncology Group
GlaxoSmithKline

Withdrawn

Pazopanib for Treating Uterine Leiomyosarcoma

Uterine Leiomyosarcoma
Shanghai Gynecologic Oncology Group
Fudan University

Not yet recruiting

Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

China
Shanghai Gynecologic Oncology Group
Fudan University

Not yet recruiting

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

China
Shanghai Gynecologic Oncology Group
Fudan University

Completed

Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer

Cervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Malignant Neoplasm of Cervix Stage IB1 | Stage IIA1 Cervical Cancer

China
AbbVie
Gynecologic Oncology Group;Australia New Zealand Gynaecological Oncology...

Terminated

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (VELIA)

Ovarian Cancer | Ovarian Neoplasm

United States, Australia, Brazil, Denmark, Israel, Japan, Korea, Republic of, New Zealand, Poland, Spain, United Kingdom
Radiation Therapy Oncology Group
National Cancer Institute (NCI); Gynecologic Oncology Group

Completed

Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer

Endometrial Cancer

United States, Norway
Far Eastern Memorial Hospital
Gynecologic Oncology Group

Recruiting

Clinical Effectiveness of First Trimester Pre-eclampsia Screening Program.

Pre-eclampsia

Taiwan
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Stage IV Endometrial Carcinoma

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus

Recurrent Uterine Corpus Sarcoma | Uterine Carcinosarcoma

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Endometrial Carcinoma

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Cervical Squamous Cell Carcinoma | Recurrent Cervical Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Endometrial Carcinoma

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Primary Peritoneal Cavity Cancer | Brenner Tumor | Recurrent Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma | Ovarian Mixed Epithelial Carcinoma | Ovarian...

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Recurrent Uterine Corpus Sarcoma | Uterine Corpus Leiomyosarcoma

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

Recurrent Ovarian Carcinoma | Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer

Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Brenner Tumor | Stage II Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian... and other conditions

United States, Japan
Shanghai Gynecologic Oncology Group
Shanghai Zhongshan Hospital

Unknown

Total/Subtotal Colectomy in Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma | Secondary Malignant Neoplasm of Large Intestine

China
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer

Endometrial Cancer

United States, Canada, Norway, United Kingdom, Australia
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer

Cervical Cancer | Vaginal Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Biomarkers in Tissue Samples From Patients With Stage I or Stage III Endometrial Cancer

Endometrial Cancer
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass

Ovarian Cancer | Fallopian Tube Cancer

United States
Eli Lilly and Company
Gynecologic Oncology Group

Completed

A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer

Ovarian Cancer | Peritoneal Cancer

United States
Eli Lilly and Company
Gynecologic Oncology Group

Completed

A Trial for Patients With Advanced/Recurrent Cervical Cancer

Cervical Intraepithelial Neoplasia | Uterine Neoplasms | Genital Neoplasms, Female

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

Uterine Carcinosarcoma | Recurrent Uterine Sarcoma

United States

Clinical Trials Sponsored by Taiwanese Gynecologic Oncology Group

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations